Written questions by Vickers.

What information his Department holds on the average number of days taken to fill a consultant-level vacancy in each of the last five years; and what assessment he has made of the potential impact of the time taken to fill consultant-level vacancies on waiting list recovery rates.

The Department does not hold data on the number of days taken to fill a consultant-level vacancy nor has it made an assessment of the potential impact of the time taken to fill consultant-level vacancies on waiting list recovery rates.NHS England published its planning guidance for 2025/26 in January 2025. This guidance sets out clear priorities for the National Health Service, including the delivery of the interim electives ambition that nationally, 65% of patients are seen within 18 weeks, along with an expected minimum 5% improvement on current performance for each trust, as set out in the Elective Reform Plan.It is for trusts and integrated care boards to manage staffing of all professions to deliver on these priorities within their agreed financial allocations.

What recent assessment he has made of the potential impact of the abolition of NHS England on the pace of workforce planning in addition to the long-term workforce plan.

No assessment has been made of the potential impact of the abolition of NHS England on the pace of workforce planning in addition to the long-term workforce plan.We will publish our 10 Year Workforce Plan by the end of this year.

What assessment she has made of the potential impact of increased business rates on the viability of large-format retail stores.

We are creating a fairer business rates system that protects the high street, supports investment, and is fit for the 21st century. From 2026-27, the Government intends to introduce permanently lower tax rates for retail, hospitality and leisure properties with rateable values (RVs) under £500,000. The Government intends to fund this by introducing a higher multiplier on properties with RVs of £500,000 or more. These high-value properties cover the majority of large distribution warehouses, including those used by the online giants. The final design of the new multipliers, including the rates, will be set at Budget 2025 so that we can take into account the upcoming revaluation outcomes, as well as the economic and fiscal context. When the new multipliers are set at Budget 2025, we intend to publish analysis of the effects of the new multiplier arrangements.

If she will make it her policy to ensure that recovered life jackets are not re-entered into circulation for use in further crossings.

The majority of life jackets seized arrive in very poor condition and may be damaged during the recovery process, and are disposed of by Border Force’s approved contractors and, where appropriate, any suitable materials are recycled.

Whether her Department holds information on the reuse of life jackets recovered from small boat crossings by criminal gangs.

The majority of life jackets seized arrive in very poor condition and may be damaged during the recovery process, and are disposed of by Border Force’s approved contractors and, where appropriate, any suitable materials are recycled.

What steps he is taking to ensure that employees in the oil and gas industry in England have adequate skills to find new employment.

We will shortly be publishing a clean energy workforce strategy which will set out our approach to upskilling and reskilling the workforce into clean energy roles through initiatives including the Energy Skills Passport, in collaboration with industry, which is helping oil and gas workers to identify routes into roles in offshore wind including construction and maintenance. The skills system is delivering training for existing workers looking to retrain or upskill into clean energy. Support includes the announcement of 10 Technical Excellence Colleges for construction, which will transform existing further education colleges to deliver the skills needed for growth-driving sectors like clean energy; the Growth and Skills levy to deliver greater flexibility for learners and employers in England; and Skill Bootcamps to address the need for clean energy skills where this reflects regional priorities.

What steps he is taking to ensure that people presenting with fragility fractures are systematically referred for a bone density scan.

Fracture Liaison Services are commissioned by integrated care boards, which are well-placed to make decisions according to local need.Our 10-Year Health Plan committed to rolling out Fracture Liaison Services across every part of the country by 2030.Officials continue to work closely with NHS England to explore a range of options to provide better quality and access to these important preventative services.

What steps his Department is taking to assess the potential impact of centralised specialist services on patient outcomes for different blood cancers.

Reducing the number of lives lost to cancer is a key aim of the National Cancer Plan, which will be published later this year. The plan will include further details on how we will improve outcomes for cancer patients, including blood cancer patients, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, ultimately driving up this country’s cancer survival rates. The National Cancer Plan will have patients at its heart, and the Department has been working closely with patient organisations and other cancer partners as part of our engagement to inform the development of the plan. This includes patient and family engagement events with partners such as Macmillan and Maggies, and engagement with blood cancer charities and the NHS Patient and Public Voice Forum.Early diagnosis is a key focus of the National Cancer Plan. It is a priority for the Government to support the National Health Service to diagnose cancer, including blood cancers, as early and quickly as possible, and to treat it faster, to improve outcomes. To tackle the late diagnoses of blood cancers, the NHS is implementing non-specific symptom pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers are one of the most common cancer types diagnosed through these pathways. We will get the NHS diagnosing blood cancers earlier and treating them faster, and we will support the NHS to increase capacity to meet the demand for diagnostic services through investment, including for magnetic resonance imaging and computed tomography scanners. Furthermore, the 10-Year Health Plan’s commitment to putting digital health at the heart of the future health service, and integrating that with a single patient record and neighbourhood health services, will mean that cancer patients will get the joined-up care they deserve.The National Cancer Plan will also seek to ensure that high-quality care is available to patients across the country, including patients in rural areas. This will build on the current national cancer audits, which are seeking to promote best practice and aim to reduce inequalities in the access to, or the quality of, treatment. Further details on the steps that will be taken to achieve this will be set out in the plan. Service providers are responsible for making clinical decisions about prioritisation in response to capacity constraints, taking into consideration national guidance, and access and waiting time standards, so that patients are prioritised.Haematopoietic stem cell transplantation (HSCT) is a potential treatment for a range of malignant and non-malignant indications, including myeloma. HSCT is a specialised service and is the commissioning responsibility of integrated care boards.NHS England is the accountable commissioner for HSCT and has published a national service specification that all commissioned HSCT services need to meet. The list of commissioned indications is covered by the NHS England Clinical Commissioning Policy available at the following link:https://www.england.nhs.uk/wp-content/uploads/2022/10/Haematopoietic-Stem-Cell-Transplantation-HSCT-All-Ages.pdfThere are currently no plans to expand the number of specialised centres that deliver HSCT treatments.Blood cancer in and of itself is not a disease that is specialised, however, some of the treatments used to manage blood cancers are within specialised services, such as HSCT. NHS England publishes national service specifications for specialised services and monitors the quality-of-service provision and patient outcomes via the NHS England quality dashboards, and in the case of HSCT, by also reviewing the service-level reports published by the British Society of Blood and Marrow Transplantation and Cellular Therapy. The findings of the reviews of these reports are discussed with NHS England regional teams who determine any appropriate action that needs to be taken with the providers within their region.

Whether his Department plans to expand the number of specialist centres for myeloma treatment.

Reducing the number of lives lost to cancer is a key aim of the National Cancer Plan, which will be published later this year. The plan will include further details on how we will improve outcomes for cancer patients, including blood cancer patients, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, ultimately driving up this country’s cancer survival rates. The National Cancer Plan will have patients at its heart, and the Department has been working closely with patient organisations and other cancer partners as part of our engagement to inform the development of the plan. This includes patient and family engagement events with partners such as Macmillan and Maggies, and engagement with blood cancer charities and the NHS Patient and Public Voice Forum.Early diagnosis is a key focus of the National Cancer Plan. It is a priority for the Government to support the National Health Service to diagnose cancer, including blood cancers, as early and quickly as possible, and to treat it faster, to improve outcomes. To tackle the late diagnoses of blood cancers, the NHS is implementing non-specific symptom pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers are one of the most common cancer types diagnosed through these pathways. We will get the NHS diagnosing blood cancers earlier and treating them faster, and we will support the NHS to increase capacity to meet the demand for diagnostic services through investment, including for magnetic resonance imaging and computed tomography scanners. Furthermore, the 10-Year Health Plan’s commitment to putting digital health at the heart of the future health service, and integrating that with a single patient record and neighbourhood health services, will mean that cancer patients will get the joined-up care they deserve.The National Cancer Plan will also seek to ensure that high-quality care is available to patients across the country, including patients in rural areas. This will build on the current national cancer audits, which are seeking to promote best practice and aim to reduce inequalities in the access to, or the quality of, treatment. Further details on the steps that will be taken to achieve this will be set out in the plan. Service providers are responsible for making clinical decisions about prioritisation in response to capacity constraints, taking into consideration national guidance, and access and waiting time standards, so that patients are prioritised.Haematopoietic stem cell transplantation (HSCT) is a potential treatment for a range of malignant and non-malignant indications, including myeloma. HSCT is a specialised service and is the commissioning responsibility of integrated care boards.NHS England is the accountable commissioner for HSCT and has published a national service specification that all commissioned HSCT services need to meet. The list of commissioned indications is covered by the NHS England Clinical Commissioning Policy available at the following link:https://www.england.nhs.uk/wp-content/uploads/2022/10/Haematopoietic-Stem-Cell-Transplantation-HSCT-All-Ages.pdfThere are currently no plans to expand the number of specialised centres that deliver HSCT treatments.Blood cancer in and of itself is not a disease that is specialised, however, some of the treatments used to manage blood cancers are within specialised services, such as HSCT. NHS England publishes national service specifications for specialised services and monitors the quality-of-service provision and patient outcomes via the NHS England quality dashboards, and in the case of HSCT, by also reviewing the service-level reports published by the British Society of Blood and Marrow Transplantation and Cellular Therapy. The findings of the reviews of these reports are discussed with NHS England regional teams who determine any appropriate action that needs to be taken with the providers within their region.

What recent estimate his Department has made of the cost savings to the NHS from the expansion of Fracture Liaison Services in England.

Potential cost savings to the National Health Service from the expansion of Fracture Liaison Services will be taken into consideration in future policy development.

What discussions his Department has had with NHS England on incorporating fracture liaison services into the national 10-Year Health Plan.

Fracture Liaison Services are commissioned by integrated care boards, which are well-placed to make decisions according to local need.Our 10-Year Health Plan committed to rolling out Fracture Liaison Services across every part of the country by 2030.Officials continue to work closely with NHS England to explore a range of options to provide better quality and access to these important preventative services.

What steps his Department is taking to ensure equitable access to osteoporosis medication and early diagnosis services across all regions of England.

In the last three years, two new drugs have been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of osteoporosis in post-menopausal women, namely abaloparatide and romosozumab. These medications help to strengthen the bones and prevent bone loss, thereby reducing the risk of fractures. The National Health Service is legally required to make funding available for treatments recommended by NICE.We have invested in 13 new bone density, or DEXA, scanners, which are expected to provide up to 29,000 extra scans per year to ensure people with bone conditions get diagnosed earlier.The National Fracture Liaison Service database is a clinically led national audit of secondary fracture prevention in England and Wales and is commissioned by the Healthcare Quality Improvement Partnership and delivered by the Royal College of Physicians. It collects and publishes data on individual Fracture Liaison Services and uses internationally recognised standards as the key performance indicators that these services are measured against. The data is publicly available.

What his planned timetable is for the national roll-out of Fracture Liaison Services.

Fracture Liaison Services are commissioned by integrated care boards, which are well-placed to make decisions according to local need.Our 10-Year Health Plan committed to rolling out Fracture Liaison Services across every part of the country by 2030.Officials continue to work closely with NHS England to explore a range of options to provide better quality and access to these important preventative services.

Whether his Department is taking steps with patient organisations to understand barriers to blood cancer care in local communities.

Reducing the number of lives lost to cancer is a key aim of the National Cancer Plan, which will be published later this year. The plan will include further details on how we will improve outcomes for cancer patients, including blood cancer patients, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, ultimately driving up this country’s cancer survival rates. The National Cancer Plan will have patients at its heart, and the Department has been working closely with patient organisations and other cancer partners as part of our engagement to inform the development of the plan. This includes patient and family engagement events with partners such as Macmillan and Maggies, and engagement with blood cancer charities and the NHS Patient and Public Voice Forum.Early diagnosis is a key focus of the National Cancer Plan. It is a priority for the Government to support the National Health Service to diagnose cancer, including blood cancers, as early and quickly as possible, and to treat it faster, to improve outcomes. To tackle the late diagnoses of blood cancers, the NHS is implementing non-specific symptom pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers are one of the most common cancer types diagnosed through these pathways. We will get the NHS diagnosing blood cancers earlier and treating them faster, and we will support the NHS to increase capacity to meet the demand for diagnostic services through investment, including for magnetic resonance imaging and computed tomography scanners. Furthermore, the 10-Year Health Plan’s commitment to putting digital health at the heart of the future health service, and integrating that with a single patient record and neighbourhood health services, will mean that cancer patients will get the joined-up care they deserve.The National Cancer Plan will also seek to ensure that high-quality care is available to patients across the country, including patients in rural areas. This will build on the current national cancer audits, which are seeking to promote best practice and aim to reduce inequalities in the access to, or the quality of, treatment. Further details on the steps that will be taken to achieve this will be set out in the plan. Service providers are responsible for making clinical decisions about prioritisation in response to capacity constraints, taking into consideration national guidance, and access and waiting time standards, so that patients are prioritised.Haematopoietic stem cell transplantation (HSCT) is a potential treatment for a range of malignant and non-malignant indications, including myeloma. HSCT is a specialised service and is the commissioning responsibility of integrated care boards.NHS England is the accountable commissioner for HSCT and has published a national service specification that all commissioned HSCT services need to meet. The list of commissioned indications is covered by the NHS England Clinical Commissioning Policy available at the following link:https://www.england.nhs.uk/wp-content/uploads/2022/10/Haematopoietic-Stem-Cell-Transplantation-HSCT-All-Ages.pdfThere are currently no plans to expand the number of specialised centres that deliver HSCT treatments.Blood cancer in and of itself is not a disease that is specialised, however, some of the treatments used to manage blood cancers are within specialised services, such as HSCT. NHS England publishes national service specifications for specialised services and monitors the quality-of-service provision and patient outcomes via the NHS England quality dashboards, and in the case of HSCT, by also reviewing the service-level reports published by the British Society of Blood and Marrow Transplantation and Cellular Therapy. The findings of the reviews of these reports are discussed with NHS England regional teams who determine any appropriate action that needs to be taken with the providers within their region.

What steps his Department is taking to consider patient feedback when developing the national cancer plan for blood cancers.

Reducing the number of lives lost to cancer is a key aim of the National Cancer Plan, which will be published later this year. The plan will include further details on how we will improve outcomes for cancer patients, including blood cancer patients, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, ultimately driving up this country’s cancer survival rates. The National Cancer Plan will have patients at its heart, and the Department has been working closely with patient organisations and other cancer partners as part of our engagement to inform the development of the plan. This includes patient and family engagement events with partners such as Macmillan and Maggies, and engagement with blood cancer charities and the NHS Patient and Public Voice Forum.Early diagnosis is a key focus of the National Cancer Plan. It is a priority for the Government to support the National Health Service to diagnose cancer, including blood cancers, as early and quickly as possible, and to treat it faster, to improve outcomes. To tackle the late diagnoses of blood cancers, the NHS is implementing non-specific symptom pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers are one of the most common cancer types diagnosed through these pathways. We will get the NHS diagnosing blood cancers earlier and treating them faster, and we will support the NHS to increase capacity to meet the demand for diagnostic services through investment, including for magnetic resonance imaging and computed tomography scanners. Furthermore, the 10-Year Health Plan’s commitment to putting digital health at the heart of the future health service, and integrating that with a single patient record and neighbourhood health services, will mean that cancer patients will get the joined-up care they deserve.The National Cancer Plan will also seek to ensure that high-quality care is available to patients across the country, including patients in rural areas. This will build on the current national cancer audits, which are seeking to promote best practice and aim to reduce inequalities in the access to, or the quality of, treatment. Further details on the steps that will be taken to achieve this will be set out in the plan. Service providers are responsible for making clinical decisions about prioritisation in response to capacity constraints, taking into consideration national guidance, and access and waiting time standards, so that patients are prioritised.Haematopoietic stem cell transplantation (HSCT) is a potential treatment for a range of malignant and non-malignant indications, including myeloma. HSCT is a specialised service and is the commissioning responsibility of integrated care boards.NHS England is the accountable commissioner for HSCT and has published a national service specification that all commissioned HSCT services need to meet. The list of commissioned indications is covered by the NHS England Clinical Commissioning Policy available at the following link:https://www.england.nhs.uk/wp-content/uploads/2022/10/Haematopoietic-Stem-Cell-Transplantation-HSCT-All-Ages.pdfThere are currently no plans to expand the number of specialised centres that deliver HSCT treatments.Blood cancer in and of itself is not a disease that is specialised, however, some of the treatments used to manage blood cancers are within specialised services, such as HSCT. NHS England publishes national service specifications for specialised services and monitors the quality-of-service provision and patient outcomes via the NHS England quality dashboards, and in the case of HSCT, by also reviewing the service-level reports published by the British Society of Blood and Marrow Transplantation and Cellular Therapy. The findings of the reviews of these reports are discussed with NHS England regional teams who determine any appropriate action that needs to be taken with the providers within their region.

What steps his Department is taking to help ensure that every NHS Trust in England commissions a Fracture Liaison Service.

Fracture Liaison Services are commissioned by integrated care boards, which are well-placed to make decisions according to local need.Our 10-Year Health Plan committed to rolling out Fracture Liaison Services across every part of the country by 2030.Officials continue to work closely with NHS England to explore a range of options to provide better quality and access to these important preventative services.

If he will take steps to issue guidance to NHS trusts on prioritising blood cancer patients for treatment when demand exceeds capacity.

Reducing the number of lives lost to cancer is a key aim of the National Cancer Plan, which will be published later this year. The plan will include further details on how we will improve outcomes for cancer patients, including blood cancer patients, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, ultimately driving up this country’s cancer survival rates. The National Cancer Plan will have patients at its heart, and the Department has been working closely with patient organisations and other cancer partners as part of our engagement to inform the development of the plan. This includes patient and family engagement events with partners such as Macmillan and Maggies, and engagement with blood cancer charities and the NHS Patient and Public Voice Forum.Early diagnosis is a key focus of the National Cancer Plan. It is a priority for the Government to support the National Health Service to diagnose cancer, including blood cancers, as early and quickly as possible, and to treat it faster, to improve outcomes. To tackle the late diagnoses of blood cancers, the NHS is implementing non-specific symptom pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers are one of the most common cancer types diagnosed through these pathways. We will get the NHS diagnosing blood cancers earlier and treating them faster, and we will support the NHS to increase capacity to meet the demand for diagnostic services through investment, including for magnetic resonance imaging and computed tomography scanners. Furthermore, the 10-Year Health Plan’s commitment to putting digital health at the heart of the future health service, and integrating that with a single patient record and neighbourhood health services, will mean that cancer patients will get the joined-up care they deserve.The National Cancer Plan will also seek to ensure that high-quality care is available to patients across the country, including patients in rural areas. This will build on the current national cancer audits, which are seeking to promote best practice and aim to reduce inequalities in the access to, or the quality of, treatment. Further details on the steps that will be taken to achieve this will be set out in the plan. Service providers are responsible for making clinical decisions about prioritisation in response to capacity constraints, taking into consideration national guidance, and access and waiting time standards, so that patients are prioritised.Haematopoietic stem cell transplantation (HSCT) is a potential treatment for a range of malignant and non-malignant indications, including myeloma. HSCT is a specialised service and is the commissioning responsibility of integrated care boards.NHS England is the accountable commissioner for HSCT and has published a national service specification that all commissioned HSCT services need to meet. The list of commissioned indications is covered by the NHS England Clinical Commissioning Policy available at the following link:https://www.england.nhs.uk/wp-content/uploads/2022/10/Haematopoietic-Stem-Cell-Transplantation-HSCT-All-Ages.pdfThere are currently no plans to expand the number of specialised centres that deliver HSCT treatments.Blood cancer in and of itself is not a disease that is specialised, however, some of the treatments used to manage blood cancers are within specialised services, such as HSCT. NHS England publishes national service specifications for specialised services and monitors the quality-of-service provision and patient outcomes via the NHS England quality dashboards, and in the case of HSCT, by also reviewing the service-level reports published by the British Society of Blood and Marrow Transplantation and Cellular Therapy. The findings of the reviews of these reports are discussed with NHS England regional teams who determine any appropriate action that needs to be taken with the providers within their region.

What progress he has made on rolling out Fracture Liaison Services in all NHS Trusts in England.

Fracture Liaison Services are commissioned by integrated care boards, which are well-placed to make decisions according to local need.Our 10-Year Health Plan committed to rolling out Fracture Liaison Services across every part of the country by 2030.Officials continue to work closely with NHS England to explore a range of options to provide better quality and access to these important preventative services.

What steps he is taking to monitor progress on access to new NHS-approved drugs for blood cancer patients.

The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based recommendations for the National Health Service on whether new medicines represent a clinically and cost-effective use of resources. NICE has been able to recommend a number of medicines for use in the NHS for the treatment of different types of blood cancer.NHS England funds NICE-recommended cancer medicines from the Cancer Drugs Fund from the point of a positive draft NICE guidance, bringing forward patient access by approximately five months than would otherwise be the case. All drugs on the Cancer Drugs Fund have reached expected uptake levels within three months of a positive NICE recommendation.

What steps he is taking to improve five-year survival rates for patients with acute myeloid leukaemia.

Reducing the number of lives lost to cancer is a key aim of the National Cancer Plan, which will be published later this year. The plan will include further details on how we will improve outcomes for cancer patients, including blood cancer patients, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, ultimately driving up this country’s cancer survival rates. The National Cancer Plan will have patients at its heart, and the Department has been working closely with patient organisations and other cancer partners as part of our engagement to inform the development of the plan. This includes patient and family engagement events with partners such as Macmillan and Maggies, and engagement with blood cancer charities and the NHS Patient and Public Voice Forum.Early diagnosis is a key focus of the National Cancer Plan. It is a priority for the Government to support the National Health Service to diagnose cancer, including blood cancers, as early and quickly as possible, and to treat it faster, to improve outcomes. To tackle the late diagnoses of blood cancers, the NHS is implementing non-specific symptom pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers are one of the most common cancer types diagnosed through these pathways. We will get the NHS diagnosing blood cancers earlier and treating them faster, and we will support the NHS to increase capacity to meet the demand for diagnostic services through investment, including for magnetic resonance imaging and computed tomography scanners. Furthermore, the 10-Year Health Plan’s commitment to putting digital health at the heart of the future health service, and integrating that with a single patient record and neighbourhood health services, will mean that cancer patients will get the joined-up care they deserve.The National Cancer Plan will also seek to ensure that high-quality care is available to patients across the country, including patients in rural areas. This will build on the current national cancer audits, which are seeking to promote best practice and aim to reduce inequalities in the access to, or the quality of, treatment. Further details on the steps that will be taken to achieve this will be set out in the plan. Service providers are responsible for making clinical decisions about prioritisation in response to capacity constraints, taking into consideration national guidance, and access and waiting time standards, so that patients are prioritised.Haematopoietic stem cell transplantation (HSCT) is a potential treatment for a range of malignant and non-malignant indications, including myeloma. HSCT is a specialised service and is the commissioning responsibility of integrated care boards.NHS England is the accountable commissioner for HSCT and has published a national service specification that all commissioned HSCT services need to meet. The list of commissioned indications is covered by the NHS England Clinical Commissioning Policy available at the following link:https://www.england.nhs.uk/wp-content/uploads/2022/10/Haematopoietic-Stem-Cell-Transplantation-HSCT-All-Ages.pdfThere are currently no plans to expand the number of specialised centres that deliver HSCT treatments.Blood cancer in and of itself is not a disease that is specialised, however, some of the treatments used to manage blood cancers are within specialised services, such as HSCT. NHS England publishes national service specifications for specialised services and monitors the quality-of-service provision and patient outcomes via the NHS England quality dashboards, and in the case of HSCT, by also reviewing the service-level reports published by the British Society of Blood and Marrow Transplantation and Cellular Therapy. The findings of the reviews of these reports are discussed with NHS England regional teams who determine any appropriate action that needs to be taken with the providers within their region.